Advances in anticancer radiopharmaceuticals

Jackson, M.R. , Falzone, N. and Vallis, K.A. (2013) Advances in anticancer radiopharmaceuticals. Clinical Oncology, 25(10), pp. 604-609. (doi: 10.1016/j.clon.2013.06.004) (PMID:23870756)

Full text not currently available from Enlighten.


This review highlights recent progress in the development of anticancer radiopharmaceuticals. Molecularly targeted radiotherapy refers to the selective delivery of radionuclides that emit charged particles, such as α particles, β or Auger electrons, to cancer cells via a targeting vector. The discovery of new molecular targets through systems biology and other approaches has widened the scope for radiopharmaceutical development. Innovations in antibody engineering and humanisation, recombinant DNA technology, conjugation chemistry and, increasingly, nanotechnology have provided new approaches to the delivery of radionuclides to cancer cells. The increased availability of radioisotopes that have not traditionally been considered for therapy, such as α particle emitters, has also broadened the indications for targeted radiotherapy.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Jackson, Dr Mark
Authors: Jackson, M.R., Falzone, N., and Vallis, K.A.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Clinical Oncology
ISSN (Online):1433-2981
Published Online:17 July 2013

University Staff: Request a correction | Enlighten Editors: Update this record